--- title: "Immunic, Inc. $IMUX Shares Bought by Avidity Partners Management LP" type: "News" locale: "en" url: "https://longbridge.com/en/news/294575589.md" description: "Avidity Partners Management LP increased its Immunic (IMUX) holdings by 42.6% in Q1, owning 6.7 million shares. Other institutions like Millennium and Laurion also significantly boosted their positions. Meanwhile, analyst ratings for Immunc remain mixed with a consensus 'Buy' rating and $47.57 price target, despite recent earnings misses and varied brokerage actions from Weiss Ratings to B. Riley." datetime: "2026-08-01T07:40:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294575589.md) - [en](https://longbridge.com/en/news/294575589.md) - [zh-HK](https://longbridge.com/zh-HK/news/294575589.md) --- # Immunic, Inc. $IMUX Shares Bought by Avidity Partners Management LP Avidity Partners Management LP lifted its holdings in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 42.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,699,411 shares of the company's stock after purchasing an additional 2,000,000 shares during the quarter. Immunic comprises about 1.5% of Avidity Partners Management LP's holdings, making the stock its 14th biggest holding. Avidity Partners Management LP owned about 49.19% of Immunic worth $7,436,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also made changes to their positions in IMUX. Nantahala Capital Management LLC acquired a new position in shares of Immunic in the fourth quarter valued at approximately $2,337,000. Millennium Management LLC increased its position in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company's stock worth $1,825,000 after acquiring an additional 2,888,829 shares during the period. Laurion Capital Management LP increased its position in shares of Immunic by 106.3% during the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company's stock worth $2,072,000 after acquiring an additional 2,000,000 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Immunic in the first quarter valued at $1,020,000. Finally, Marshall Wace LLP raised its stake in shares of Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company's stock valued at $541,000 after acquiring an additional 486,468 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock. ## Immunic Stock Performance Shares of Immunic stock opened at $13.97 on Friday. The company has a market cap of $190.27 million, a P/E ratio of -2.50 and a beta of 1.37. The firm has a fifty day moving average of $14.29 and a two-hundred day moving average of $11.47. Immunic, Inc. has a one year low of $5.06 and a one year high of $15.84. Immunic (NASDAQ:IMUX - Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). As a group, equities analysts predict that Immunic, Inc. will post -4.54 earnings per share for the current year. ## Analysts Set New Price Targets A number of brokerages have recently commented on IMUX. Weiss Ratings reissued a "sell (d-)" rating on shares of Immunic in a research report on Friday, May 29th. B. Riley Financial decreased their price target on shares of Immunic from $40.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 22nd. Lifesci Capital upgraded shares of Immunic to a "strong-buy" rating in a research note on Monday, May 4th. Wall Street Zen downgraded Immunic from a "hold" rating to a "sell" rating in a report on Sunday, April 19th. Finally, D. Boral Capital lowered Immunic from a "buy" rating to a "hold" rating in a research report on Wednesday, April 15th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $47.57. **Check Out Our Latest Analysis on Immunic** ## About Immunic (Free Report) Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients. Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis. ## Recommended Stories - Five stocks we like better than Immunic - Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector - Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case - Apple’s Record Quarter Could Not Outrun Its Guidance Problem - McKesson's Compounding Keeps Adding Up **Want to see what other hedge funds are holding IMUX?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunic, Inc. (NASDAQ:IMUX - Free Report). _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Immunic Right Now? Before you consider Immunic, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list. While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md) - [RILY.US](https://longbridge.com/en/quote/RILY.US.md) - [CVX.US](https://longbridge.com/en/quote/CVX.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [AAPL.US](https://longbridge.com/en/quote/AAPL.US.md) - [MCK.US](https://longbridge.com/en/quote/MCK.US.md) - [RILYL.US](https://longbridge.com/en/quote/RILYL.US.md) - [RILYG.US](https://longbridge.com/en/quote/RILYG.US.md) - [RILYN.US](https://longbridge.com/en/quote/RILYN.US.md) - [RILYK.US](https://longbridge.com/en/quote/RILYK.US.md) - [RILYP.US](https://longbridge.com/en/quote/RILYP.US.md) - [RILYZ.US](https://longbridge.com/en/quote/RILYZ.US.md) - [RILYT.US](https://longbridge.com/en/quote/RILYT.US.md) ## Related News & Research - [Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | IMUX Stock News](https://longbridge.com/en/news/295521858.md) - [Immunic files Form 3 for director Elena Ridloff, reporting no beneficial ownership](https://longbridge.com/en/news/295459919.md) - [Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program](https://longbridge.com/en/news/295534519.md) - [Assenagon Asset Management S.A. Acquires New Position in Integer Holdings Corporation $ITGR](https://longbridge.com/en/news/296015510.md) - [45,236 Shares in AMN Healthcare Services Inc $AMN Acquired by Assenagon Asset Management S.A.](https://longbridge.com/en/news/295994171.md)